In agreement with these data, Bastaki et al. [35] and Crosby et al. [36], demonstrated that combining anti-PD-1/PD-L1 therapy with immune-stimulating vaccines can be considered an effective therapeutic regimen in breast cancer. The gene discussed is PDCD1; the disease is breast carcinoma.